NEW YORK (GenomeWeb) – BioMérieux today announced that BioFire's FilmArray Gastrointestinal Panel has received 510(k) clearance for marketing by the US Food and Drug Administration.

The 22-target panel is for diagnosing infectious diarrhea and includes bacteria, viruses, and parasites in one test. According to BioMérieux, the test is the most comprehensive gastrointestinal panel to be cleared by FDA and contains several pathogens that have received FDA clearance for the first time.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.